Ascentage Pharma International Statistics
Share Statistics
Ascentage Pharma International has 90.54M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 90.54M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 83 |
| FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 13K, so 0.01% of the outstanding
shares have been sold short.
| Short Interest | 13K |
| Short % of Shares Out | 0.01% |
| Short % of Float | 0.02% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -23.63 and the forward
PE ratio is 29.4.
Ascentage Pharma International's PEG ratio is
0.25.
| PE Ratio | -23.63 |
| Forward PE | 29.4 |
| PS Ratio | 9.77 |
| Forward PS | 9.4 |
| PB Ratio | 36.26 |
| P/FCF Ratio | -70.62 |
| PEG Ratio | 0.25 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Ascentage Pharma International.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.26,
with a Debt / Equity ratio of 6.32.
| Current Ratio | 1.26 |
| Quick Ratio | 1.26 |
| Debt / Equity | 6.32 |
| Debt / EBITDA | -7.02 |
| Debt / FCF | -12.3 |
| Interest Coverage | -5.74 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,729,541.45 |
| Profits Per Employee | $-715,049.38 |
| Employee Count | 567 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 4.41 |
Taxes
| Income Tax | 10.43M |
| Effective Tax Rate | -2.64% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0.78, so Ascentage Pharma International's
price volatility has been higher than the market average.
| Beta | 0.78 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 22.66 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 55.08 |
| Average Volume (20 Days) | 30,806 |
Income Statement
In the last 12 months, Ascentage Pharma International had revenue of 980.65M
and earned -405.43M
in profits. Earnings per share was -0.75.
| Revenue | 980.65M |
| Gross Profit | 951.57M |
| Operating Income | -369.73M |
| Net Income | -405.43M |
| EBITDA | -237.63M |
| EBIT | -330.8M |
| Earnings Per Share (EPS) | -0.75 |
Full Income StatementBalance Sheet
The company has 1.24B in cash and 1.67B in
debt, giving a net cash position of -431.92M.
| Cash & Cash Equivalents | 1.24B |
| Total Debt | 1.67B |
| Net Cash | -431.92M |
| Retained Earnings | -5.77B |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -111.36M
and capital expenditures -24.29M, giving a free cash flow of -135.65M.
| Operating Cash Flow | -111.36M |
| Capital Expenditures | -24.29M |
| Free Cash Flow | -135.65M |
| FCF Per Share | -1.8 |
Full Cash Flow StatementMargins
Gross margin is 97.03%, with operating and profit margins of -37.7% and -41.34%.
| Gross Margin | 97.03% |
| Operating Margin | -37.7% |
| Pretax Margin | -40.31% |
| Profit Margin | -41.34% |
| EBITDA Margin | -24.23% |
| EBIT Margin | -37.7% |
| FCF Margin | -13.83% |
